1 month retatrutide Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide 3-Month Results: Weight Loss

VSMC prolif.: vascular smooth muscle cell proliferation

However, as we embark on a weight management journey, it's crucial to consider the long-term efficacy and sustainability of these treatments

*Average weight loss based on 68 and 72 week clinical trials studying semaglutide (2.4 mg) and tirzepatide (10-15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related health condition, the average weight loss was 15% and 20% respectively

However, patients should be cautioned that exercise capacity may be temporarily reduced during the initial treatment period, and expectations should be adjusted accordingly

Preventive cardiology is not separate from brain health

This clear window at the end of the week is a great time to focus on nutrient-dense meals and more vigorous exercise